Substituted isoindolones and their use as cyclic GMP modulators in medicaments

US6344468B1 · kind B1 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Ursula Schindler · Bad Soden, DE
• Karl Schoenafinger · Alzenau, DE
• Hartmut Strobel · Liederbach, DE
• Viola Groehn · Dachsen, CH

Key dates

• Filing date: Oct 6, 2000
• Grant date: Feb 5, 2002
• Expiry date: Oct 6, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to substituted isoindolone derivatives of the formula I, in which R1, R2, R3, R4, R5, R6 and R7 are as defined in the claims, which are useful pharmaceutically active compounds for the therapy and prophylaxis of illnesses, for example cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of illnesses which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned illnesses and for preparing pharmaceuticals for these, and also pharmaceutical preparations which comprise compounds of the formula I.